Mukai et al.’s 499-person Phase 2b schizophrenia trial tested whether higher, sustained PDE10A inhibition could turn MK-8189 into a non-D2 antipsychotic; it did not. At week 6, MK-8189 missed the PANSS total endpoint at 16 mg (−2.8 points vs. placebo; 95% CI −8.3 to 2.6; P = 0.241) and 24 mg (−0.7 points; 95% CI …
Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysis of the JEWEL Phase 3 trial pulls that number apart, looking separately at five symptom domains and at all 30 individual items of the PANSS …
Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42 times the rate of White Americans, and they also score higher on negative-symptom measures than White patients carrying the same diagnosis.2 A 2026 paper by Spann and colleagues asks why. Research Highlights Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42x the rate of White Americans, …